Publication analysis · Module 3
SURMOUNT-1: interpreting a multigroup obesity trial
SURMOUNT-1 randomized 2,539 adults with overweight or obesity, excluding diabetes, to three weekly tirzepatide groups or placebo for 72 weeks. Mean weight changes were −15.0%, −19.5%, and −20.9% in the 5-, 10-, and 15-mg study groups, respectively, versus −3.1% with placebo. These amounts identify trial groups, not an administration recommendation.
Original publication
Tirzepatide Once Weekly for the Treatment of Obesity
DOI 10.1056/NEJMoa2206038 · PMID 35658024 · Citation pending verification
Educational information for healthcare professionals and the general public. Not individual medical advice, diagnosis, treatment, or a recommendation to use a compound.
Study and main findings
SURMOUNT-1 randomized 2,539 adults with overweight or obesity, excluding diabetes, to three weekly tirzepatide groups or placebo for 72 weeks. Mean weight changes were −15.0%, −19.5%, and −20.9% in the 5-, 10-, and 15-mg study groups, respectively, versus −3.1% with placebo. These amounts identify trial groups, not an administration recommendation. Adverse events led to treatment discontinuation in 4.3%, 7.1%, and 6.2% of the respective tirzepatide groups, compared with 2.6% with placebo. Gastrointestinal events were the most common adverse events. Eli Lilly funded the trial.
Interpretation
Separate randomized groups allow the reader to examine the tested interventions within a common trial framework. The molecular description of dual GIP/GLP-1 agonism explains a rationale, but the clinical conclusion depends on measured outcomes and the study design rather than receptor count.
Limits of the conclusion
These findings do not establish an individual response, the performance of every preparation sold as tirzepatide, or superiority over a drug studied in a separate trial. Percent weight change also should not be substituted for an endpoint that the quoted comparison did not test.
How to read it critically
Keep the estimand and follow-up period attached to the reported percentages. A useful review also asks about tolerability, discontinuation, missing data, sponsor involvement, and applicability to populations outside the eligibility criteria. An educational summary should report benefits and limitations together.
Original publication
References
Bibliographic sources shown for transparency. Citation verification pending; no citation is marked verified.
Related resources
Publication analysis · Module 3
STEP 9: weight, knee pain and function
STEP 9 randomized 407 adults with obesity and painful knee osteoarthritis to semaglutide or placebo for 68 weeks, with lifestyle counseling in both groups. Weight and WOMAC pain scores improved more with semaglutide; physical function also improved. Gastrointestinal problems were the most common reason for treatment discontinuation.
Publication analysis · Module 3
BELIEVE: body composition is not the same as function
BELIEVE was a randomized phase 2 trial in 507 adults with obesity, excluding diabetes. It compared bimagrumab, semaglutide, combinations and placebo over 48 weeks, followed by an open-label extension. Bimagrumab is an investigational monoclonal antibody, not a peptide agonist.
Publication analysis · Module 3
Semaglutide and alcohol: an early randomized trial
A nine-week phase 2 trial randomized 48 adults with alcohol use disorder who were not seeking treatment to semaglutide or placebo. Laboratory alcohol consumption and some weekly drinking and craving measures improved. Average drinks per calendar day and the number of drinking days did not significantly change.